Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists
摘要:
S1P(1) receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P(1) receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl) butanoic acid S1P(1) receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.
Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists
摘要:
S1P(1) receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P(1) receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl) butanoic acid S1P(1) receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.
Improved Substrate Scope in the Potassium Hexacyanoferrate(II)-Based Cyanation for the Synthesis of Benzonitriles and Their Heterocyclic Analogues
作者:Jeffery Richardson、Simon P. Mutton
DOI:10.1021/acs.joc.8b00515
日期:2018.5.4
The use of Pd(DPEPhos)Cl2 (P26) as a catalyst for the formation of benzonitriles and their heterocyclic analogues provides excellent complementarity to existing catalysts, allowing highly electron-deficient heterocyclic arylhalides to be efficiently converted to the corresponding nitriles usingK4[Fe(CN)6]) as cyanidesource. This catalyst significantly enhances the scope of this reaction to include
Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis
申请人:Cook James
公开号:US20070105851A1
公开(公告)日:2007-05-10
This invention relates to a compound of Formula (I): (I) and its use in treating hyper-proliferative disorders and diseases associated with angiogenesis.
本发明涉及一种式(I)的化合物:(I),以及其在治疗与血管生成相关的高增殖性疾病和疾病中的应用。
Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors
申请人:UGOLINI Antonio
公开号:US20090253697A1
公开(公告)日:2009-10-08
The disclosure relates to compounds of formula (I):
wherein R1, R2, and R3 are as defined in the disclosure, compositions comprising said compounds, methods for their preparation, intermediates thereto, and the use thereof, particularly as medicaments.